hpSC-Derived Joint Cells

About International Stem Cell

International Stem Cell Corporation (ISCO) is advancing a novel regenerative medicine platform using human parthenogenetic stem cells (hpSCs) to develop immune-matched, off-the-shelf therapies. Its core mission is to address the major scalability and compatibility limitations of traditional allogeneic cell therapies by creating a bank of stem cell lines that could match a large percentage of the global population. The company's strategy is focused on translating its platform into clinical treatments for neurological, joint, and liver disorders where cell therapy has shown promise but is limited by cell supply. ISCO is led by a scientifically experienced management team and supported by a notable scientific advisory board.

Therapeutic Areas